Abstract
Backgrounds: This research was conducted to investigate the influencing factors for the prognosis among patients with sepsis/septic shock and the assessment values of the dose of noradrenaline for patient prognosis.
Methods :126 patients with sepsis/septic shock were retrospectively selected and enrolled into survival group (stable disease/discharge, n=91 cases) and death group (voluntary discharge and death, n=35 cases). After that, logistic regression analysis was implemented for the analysis of influencing factors for the prognosis and receiver operating characteristic curve (ROC) was utilized to assess the prognostic values of noradrenaline. Logistic regression analysis was performed for the analysis of procalcitonin (PCT) expression, the scores for high acute physiology and chronic health evaluatin II (APACHE II) and high sepsis related organ failure assessment (SOFA), and large dose of noradrenaline 37 h to 48 h after treatment.
Results: They were the independent risk factors for death among patients with sepsis/septic shock (P<0.05). Median survival time (MST) was shorter among patients in high-dose group (9.56d) than among patients in low-dose group (20.67d) (P<0.05).
Conclusion: High PCT expression, the scores for high APACHE II and high SOFA, and large dose of noradrenaline 37 h to 48 h after treatment affected the prognosis among patients with sepsis/septic shock. In addition, the dose of noradrenaline could reflect the prognosis.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.